Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection

被引:32
作者
Tursi, A
Cammarota, G
Montalto, M
Papa, A
Veneto, G
Cuoco, L
Trua, F
Branca, G
Fedeli, G
Gasbarrini, G
机构
[1] UNIV CATTOLICA SACRO CUORE,DEPT INTERNAL MED,DIV GASTROENTEROL,I-00168 ROME,ITALY
[2] UNIV CATTOLICA SACRO CUORE,INST MICROBIOL,I-00168 ROME,ITALY
关键词
D O I
10.1111/j.0953-0673.1996.00285.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The aim of our study was to compare two 1-week, low-dose triple therapies for Helicobacter pylori eradication. Methods: One hundred consecutive patients, suffering from dyspeptic symptoms with H. pylori infection, were randomly allocated to 7 days of treatment with omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and either tinidazole 500 mg b.d. (group A: n = 50, 19 with peptic ulcer) or amoxycillin 1000 mg b.d. (group B: n = 50, 20 with peptic ulcer). H. pylori-status was evaluated by means of histology, culture and urease test, at entry and 8 weeks after treatment. Results: Three patients did not complete the treatment. H. pylori eradication was obtained in 35 patients from group A (73%) (95% CI, 55-82%) and in 40 patients from group B (82%) (95% CI, 66-90%). On intention-to-treat analysis, the rates of eradication were similar. Side-effects occurred in seven patients from group A (14.58%) and in four patients from group B (8.33%), but none discontinued therapy because of side-effects. Conclusion: Both triple 1-week, low-dose omeprazole therapies gave good eradication rates with infrequent side-effects.
引用
收藏
页码:285 / 288
页数:4
相关论文
共 18 条
[1]  
ALASSI MT, 1994, ALIMENT PHARM THERAP, V8, P453
[2]   SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI [J].
BAZZOLI, F ;
ZAGARI, RM ;
FOSSI, S ;
POZZATO, P ;
ALAMPI, G ;
SIMONI, P ;
SOTTILI, S ;
RODA, A ;
RODA, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) :773-777
[3]  
Burette A., 1995, Gut, V37, pA89
[4]   THE BEST THERAPY FOR HELICOBACTER-PYLORI INFECTION - SHOULD EFFICACY OR SIDE-EFFECT PROFILE DETERMINE OUR CHOICE [J].
DEBOER, WA ;
TYTGAT, GNJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 (05) :401-407
[5]  
GLUPCZYNSKI Y, 1990, AM J GASTROENTEROL, V85, P1545
[6]  
GODDARD A, 1995, EUR J GASTROEN HEPAT, V7, P1
[7]  
Goddard A. F., 1995, Gut, V37, pA88
[8]   SUSCEPTIBILITY OF CAMPYLOBACTER-PYLORI TO MACROLIDES AND FLUOROQUINOLONES [J].
HARDY, DJ ;
HANSON, CW ;
HENSEY, DM ;
BEYER, JM ;
FERNANDES, PB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (05) :631-636
[9]  
Jaup B. H., 1994, American Journal of Gastroenterology, V89, P1400
[10]  
LABENZ J, 1995, EUR J GASTROEN HEPAT, V7, P9